{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:44:59Z","timestamp":1794620699001,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005307","name":"Direction G\u00e9n\u00e9rale de la Recherche Scientifique et du D\u00e9veloppement Technologique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13832-7","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:39:06Z","timestamp":1741851546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers"],"prefix":"10.1186","volume":"25","author":[{"given":"Rima Saad","family":"Bouzid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhia","family":"Bouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Housna","family":"Labed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Serhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dounia","family":"Hellal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilia","family":"Oumeddour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Boudhiaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massouda","family":"Ibrir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hachani","family":"Khadraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghania","family":"Belaaloui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"13832_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149:778\u201389.","journal-title":"Int J Cancer"},{"key":"13832_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5858\/134.6.907","volume":"134","author":"MEH Hammond","year":"2010","unstructured":"Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Arch Pathol Lab Med. 2010;134:25.","journal-title":"Arch Pathol Lab Med"},{"key":"13832_CR3","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update. JCO. 2013;31:3997\u20134013.","journal-title":"JCO"},{"key":"13832_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"13832_CR5","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1089\/jwh.2010.2558","volume":"20","author":"LM Hines","year":"2011","unstructured":"Hines LM, Risendal B, Byers T, Mengshol S, Lowery J, Singh M. Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women. J Womens Health (Larchmt). 2011;20:1543\u201350.","journal-title":"J Womens Health (Larchmt)"},{"key":"13832_CR6","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"13832_CR7","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann BD, Jovanovi\u0107 B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE. 2016;11: e0157368.","journal-title":"PLoS ONE"},{"key":"13832_CR8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clin Cancer Res. 2015;21:1688\u201398.","journal-title":"Clin Cancer Res"},{"key":"13832_CR9","doi-asserted-by":"crossref","unstructured":"Pareja F, Geyer FC, Marchi\u00f2 C, Burke KA, Weigelt B, Reis-Filho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. npj Breast Cancer. 2016;2:16036.","DOI":"10.1038\/npjbcancer.2016.36"},{"key":"13832_CR10","doi-asserted-by":"publisher","first-page":"1611162","DOI":"10.3389\/pore.2023.1611162","volume":"29","author":"M Leeha","year":"2023","unstructured":"Leeha M, Kanokwiroon K, Laohawiriyakamol S, Thongsuksai P. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance. Pathol Oncol Res. 2023;29:1611162.","journal-title":"Pathol Oncol Res"},{"key":"13832_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA A Cancer J Clinicians. 2022;72:524\u201341.","journal-title":"CA A Cancer J Clinicians"},{"key":"13832_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1200\/GO.20.00054","volume":"6","author":"A Kulkarni","year":"2020","unstructured":"Kulkarni A, Kelkar DA, Parikh N, Shashidhara LS, Koppiker CB, Kulkarni M. Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer. JCO Glob Oncol. 2020;6:1052\u201362.","journal-title":"JCO Glob Oncol"},{"key":"13832_CR13","doi-asserted-by":"crossref","unstructured":"Lin C-H, Yap YS, Lee K-H, Im S-A, Naito Y, Yeo W, et al. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. JNCI: Journal of the National Cancer Institute. 2019;111:1298\u2013306.","DOI":"10.1093\/jnci\/djz090"},{"key":"13832_CR14","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/cancers15235586","volume":"15","author":"CD Ubbaonu","year":"2023","unstructured":"Ubbaonu CD, Chang J, Ziogas A, Mehta RS, Kansal KJ, Zell JA. Disparities in Receipt of National Comprehensive Cancer Network Guideline-Adherent Care and Outcomes among Women with Triple-Negative Breast Cancer by Race\/Ethnicity, Socioeconomic Status, and Insurance Type. Cancers. 2023;15:5586.","journal-title":"Cancers"},{"key":"13832_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/0008-5472.CAN-20-3094","volume":"81","author":"F Wang","year":"2021","unstructured":"Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu X-O. Racial\/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer. Can Res. 2021;81:1163\u201370.","journal-title":"Can Res"},{"key":"13832_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.18632\/oncotarget.26559","volume":"10","author":"YC Ding","year":"2019","unstructured":"Ding YC, Steele L, Warden C, Wilczynski S, Mortimer J, Yuan Y, et al. Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity. Oncotarget. 2019;10:198\u2013208.","journal-title":"Oncotarget"},{"key":"13832_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y-Z Jiang","year":"2019","unstructured":"Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35:428-440.e5.","journal-title":"Cancer Cell"},{"key":"13832_CR18","doi-asserted-by":"publisher","first-page":"e055735","DOI":"10.1136\/bmjopen-2021-055735","volume":"12","author":"SM Hercules","year":"2022","unstructured":"Hercules SM, Alnajar M, Chen C, Mladjenovic SM, Shipeolu BA, Perkovic O, et al. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open. 2022;12: e055735.","journal-title":"BMJ Open"},{"key":"13832_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/PAI.0000000000000897","volume":"29","author":"S Kumar","year":"2021","unstructured":"Kumar S, Bal A, Das A, Bhattacharyya S, Laroiya I, Khare S, et al. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers. Appl Immunohistochem Mol Morphol. 2021;29:251\u20137.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"13832_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-021-06437-8","volume":"191","author":"T-K Yoo","year":"2022","unstructured":"Yoo T-K, Kang J, Lee A, Chae BJ. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. Breast Cancer Res Treat. 2022;191:599\u2013610.","journal-title":"Breast Cancer Res Treat"},{"key":"13832_CR21","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","volume":"25","author":"S Zhao","year":"2020","unstructured":"Zhao S, Ma D, Xiao Y, Li X-M, Ma J-L, Zhang H, et al. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Oncologist. 2020;25:e1481\u201391.","journal-title":"Oncologist"},{"key":"13832_CR22","unstructured":"Edge SB, AJCC, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010."},{"key":"13832_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/bjc.1987.230","volume":"56","author":"J Todd","year":"1987","unstructured":"Todd J, Dowle C, Williams M, Elston C, Ellis I, Hinton C, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987;56:489\u201392.","journal-title":"Br J Cancer"},{"key":"13832_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77:181\u20135.","journal-title":"Histopathology"},{"key":"13832_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259\u201371.","journal-title":"Ann Oncol"},{"key":"13832_CR26","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155\u201368.","journal-title":"Mod Pathol"},{"key":"13832_CR27","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206\u201323.","journal-title":"Ann Oncol"},{"key":"13832_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25\u201332.","journal-title":"Cancer"},{"key":"13832_CR29","unstructured":"Sunar V, T Dogan H, Sarici F, Ates O, Akin S, Baspinar B, et al. Association between androgen receptor status and prognosis in triple negative breast cancer. J BUON. 2018;23:1325\u201330."},{"key":"13832_CR30","doi-asserted-by":"publisher","first-page":"e1003","DOI":"10.1016\/j.clbc.2018.02.002","volume":"18","author":"N Yamashita","year":"2018","unstructured":"Yamashita N, Tokunaga E, Iimori M, Inoue Y, Tanaka K, Kitao H, et al. Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer. Clin Breast Cancer. 2018;18:e1003\u20139.","journal-title":"Clin Breast Cancer"},{"key":"13832_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/pin.12560","volume":"67","author":"A Katayama","year":"2017","unstructured":"Katayama A, Handa T, Komatsu K, Togo M, Horiguchi J, Nishiyama M, et al. Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome. Pathol Int. 2017;67:404\u201313.","journal-title":"Pathol Int"},{"key":"13832_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00404-021-06198-1","volume":"305","author":"N Karsten","year":"2022","unstructured":"Karsten N, Kolben T, Mahner S, Beyer S, Meister S, Kuhn C, et al. The role of E-Cadherin expression in primary site of breast cancer. Arch Gynecol Obstet. 2022;305:913\u201320.","journal-title":"Arch Gynecol Obstet"},{"key":"13832_CR33","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/02841860802047411","volume":"47","author":"J Alsner","year":"2008","unstructured":"Alsner J, Jensen V, Kyndi M, Vrou Offersen B, Vu P, B\u00f8rresen-Dale A-L, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008;47:600\u20137.","journal-title":"Acta Oncol"},{"key":"13832_CR34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2559.2007.02638.x","volume":"50","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AHS, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50:434\u20138.","journal-title":"Histopathology"},{"key":"13832_CR35","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/modpathol.2013.97","volume":"26","author":"JR Won","year":"2013","unstructured":"Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, et al. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol. 2013;26:1438\u201350.","journal-title":"Mod Pathol"},{"key":"13832_CR36","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3892\/ol.2016.4778","volume":"12","author":"Y-X Liu","year":"2016","unstructured":"Liu Y-X, Wang K-R, Xing H, Zhai X-J, Wang L-P, Wang W. Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol Lett. 2016;12:1240\u201356.","journal-title":"Oncol Lett"},{"key":"13832_CR37","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MCU Cheang","year":"2008","unstructured":"Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clin Cancer Res. 2008;14:1368\u201376.","journal-title":"Clin Cancer Res"},{"key":"13832_CR38","unstructured":"Choi J, Jung W-H, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histology and Histopathology. 2012;:1481\u201393."},{"key":"13832_CR39","doi-asserted-by":"publisher","first-page":"e1123","DOI":"10.1016\/j.clbc.2018.03.012","volume":"18","author":"S Kim","year":"2018","unstructured":"Kim S, Moon B-I, Lim W, Park S, Cho MS, Sung SH. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. Clin Breast Cancer. 2018;18:e1123\u201332.","journal-title":"Clin Breast Cancer"},{"key":"13832_CR40","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","volume":"10","author":"TO Nielsen","year":"2004","unstructured":"Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clin Cancer Res. 2004;10:5367\u201374.","journal-title":"Clin Cancer Res"},{"key":"13832_CR41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1309\/AJCPRMD3ARUO5WPN","volume":"134","author":"LM Sutton","year":"2010","unstructured":"Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D, Rakheja D, et al. Intratumoral Expression Level of Epidermal Growth Factor Receptor and Cytokeratin 5\/6 Is Significantly Associated With Nodal and Distant Metastases in Patients With Basal-like Triple-Negative Breast Carcinoma. Am J Clin Pathol. 2010;134:782\u20137.","journal-title":"Am J Clin Pathol"},{"key":"13832_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-008-0206-z","volume":"116","author":"G Viale","year":"2009","unstructured":"Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with the \u201ctriple-negative\u201d phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116:317\u201328.","journal-title":"Breast Cancer Res Treat"},{"key":"13832_CR43","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1038\/s41598-020-63310-2","volume":"10","author":"A El Guerrab","year":"2020","unstructured":"El Guerrab A, Bamdad M, Bignon Y-J, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020;10:6367.","journal-title":"Sci Rep"},{"key":"13832_CR44","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1535-7163.MCT-10-0925","volume":"10","author":"T Liu","year":"2011","unstructured":"Liu T, Yacoub R, Taliaferro-Smith LD, Sun S-Y, Graham TR, Dolan R, et al. Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells. Mol Cancer Ther. 2011;10:1460\u20139.","journal-title":"Mol Cancer Ther"},{"key":"13832_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/BCTT.S390017","volume":"15","author":"J Ma","year":"2023","unstructured":"Ma J, Dong C, Cao Y-Z, Ma B-L. Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins. BCTT. 2023;15:11\u201324.","journal-title":"BCTT"},{"key":"13832_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/ph14060589","volume":"14","author":"KS You","year":"2021","unstructured":"You KS, Yi YW, Cho J, Park J-S, Seong Y-S. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals. 2021;14:589.","journal-title":"Pharmaceuticals"},{"key":"13832_CR47","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1002\/cti2.1135","volume":"9","author":"L Xia","year":"2020","unstructured":"Xia L, Zheng Z, Liu J, Chen Y, Ding J, Xia N, et al. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin & Trans Imm. 2020;9: e1135.","journal-title":"Clin & Trans Imm"},{"key":"13832_CR48","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10:2815.","journal-title":"Sci Rep"},{"key":"13832_CR49","first-page":"353","volume":"4","author":"D Safarpour","year":"2014","unstructured":"Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014;4:353\u201368.","journal-title":"Am J Cancer Res"},{"key":"13832_CR50","doi-asserted-by":"publisher","first-page":"46482","DOI":"10.18632\/oncotarget.10208","volume":"7","author":"C Wang","year":"2016","unstructured":"Wang C, Pan B, Zhu H, Zhou Y, Mao F, Lin Y, et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget. 2016;7:46482\u201391.","journal-title":"Oncotarget"},{"key":"13832_CR51","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","volume":"19","author":"A Gucalp","year":"2013","unstructured":"Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. Clin Cancer Res. 2013;19:5505\u201312.","journal-title":"Clin Cancer Res"},{"key":"13832_CR52","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O\u2019Shaughnessy J, et al. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. JCO. 2018;36:884\u201390.","journal-title":"JCO"},{"key":"13832_CR53","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16:100.","journal-title":"J Hematol Oncol"},{"key":"13832_CR54","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr2635","volume":"12","author":"A Prat","year":"2010","unstructured":"Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.","journal-title":"Breast Cancer Res"},{"key":"13832_CR55","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00439-013-1299-y","volume":"132","author":"L Melchor","year":"2013","unstructured":"Melchor L, Ben\u00edtez J. The complex genetic landscape of familial breast cancer. Hum Genet. 2013;132:845\u201363.","journal-title":"Hum Genet"},{"key":"13832_CR56","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/cancers13061391","volume":"13","author":"I Ruscito","year":"2021","unstructured":"Ruscito I, Gasparri ML, De Marco MP, Costanzi F, Besharat AR, Papadia A, et al. The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis. Cancers. 2021;13:1391.","journal-title":"Cancers"},{"key":"13832_CR57","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1038\/sj.onc.1202847","volume":"18","author":"U-S Khoo","year":"1999","unstructured":"Khoo U-S, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, et al. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene. 1999;18:4643\u20136.","journal-title":"Oncogene"},{"key":"13832_CR58","doi-asserted-by":"crossref","unstructured":"Teixeira LA, Candido Dos Reis FJ. Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review. J Clin Pathol. 2020;73:191\u20136.","DOI":"10.1136\/jclinpath-2019-206276"},{"key":"13832_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/CBM-150550","volume":"16","author":"H Nomura","year":"2016","unstructured":"Nomura H, Kataoka F, Aoki D, Jinno H, Kitagawa Y, Sato Y, et al. Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer. CBM. 2016;16:145\u201352.","journal-title":"CBM"},{"key":"13832_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/ijmr.IJMR_4605_20","volume":"158","author":"F Khan","year":"2023","unstructured":"Khan F, Agarwal P, Gupta S, Maurya M, Singh P, Agarwal A, et al. BRCA1 promoter methylation & its immunohistochemical correlation in sporadic breast cancer. Indian J Med Res. 2023;158:47.","journal-title":"Indian J Med Res"},{"key":"13832_CR61","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ijc.30143","volume":"139","author":"R Bu","year":"2016","unstructured":"Bu R, Siraj AK, Al-Obaisi KAS, Beg S, Al Hazmi M, Ajarim D, et al. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Intl Journal of Cancer. 2016;139:1091\u20137.","journal-title":"Intl Journal of Cancer"},{"key":"13832_CR62","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1369\/jhc.7A7209.2007","volume":"55","author":"FH Vaz","year":"2007","unstructured":"Vaz FH, Machado PM, Brand\u00e3o RD, Laranjeira CT, Eug\u00e9nio JS, Fernandes AH, et al. Familial Breast\/Ovarian Cancer and BRCA1\/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients. J Histochem Cytochem. 2007;55:1105\u201313.","journal-title":"J Histochem Cytochem"},{"key":"13832_CR63","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"13832_CR64","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"13832_CR65","doi-asserted-by":"crossref","unstructured":"Vidula N, Damodaran S, Bhave MA, Rugo HS, Blouch E, Ruffle-Deignan NR, et al. Phase II study of a PARP inhibitor in somatic BRCA1\/2 mutant metastatic breast cancer (MBC). JCO. 2023;41 16_suppl:TPS1134\u2013TPS1134.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1134"},{"key":"13832_CR66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Targ Oncol. 2021;16:255\u201382.","journal-title":"Targ Oncol"},{"key":"13832_CR67","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim YH, Garc\u00eda-Garc\u00eda C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K Inhibition Impairs BRCA1\/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discov. 2012;2:1036\u201347.","journal-title":"Cancer Discov"},{"key":"13832_CR68","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/cells9112358","volume":"9","author":"O Treeck","year":"2020","unstructured":"Treeck O, Sch\u00fcler-Toprak S, Ortmann O. Estrogen Actions in Triple-Negative Breast Cancer. Cells. 2020;9:2358.","journal-title":"Cells"},{"key":"13832_CR69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biopha.2018.11.136","volume":"111","author":"M Sang","year":"2019","unstructured":"Sang M, Meng L, Ma C, Liu S, Sang M, Chang S, et al. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction. Biomed Pharmacother. 2019;111:169\u201377.","journal-title":"Biomed Pharmacother"},{"key":"13832_CR70","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15244","author":"AA Hashmi","year":"2021","unstructured":"Hashmi AA, Sajid A, Hussain M, Zia S, Islam S, Diwan MA, et al. Mutant Phenotype p53 Immunohistochemical Expression Is Associated With Poor Prognostic Parameters and Disease-Free Survival in Triple-Negative Metaplastic Breast Carcinoma. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.15244.","journal-title":"Cureus"},{"key":"13832_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PAJ Muller","year":"2013","unstructured":"Muller PAJ, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2\u20138.","journal-title":"Nat Cell Biol"},{"key":"13832_CR72","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-22-1124","volume":"82","author":"J Patterson-Fortin","year":"2022","unstructured":"Patterson-Fortin J, Bose A, Tsai W-C, Grochala C, Nguyen H, Zhou J, et al. Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53 -Mutant Cancers. Can Res. 2022;82:3815\u201329.","journal-title":"Can Res"},{"key":"13832_CR73","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","volume":"8","author":"M Efremova","year":"2017","unstructured":"Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. Front Immunol. 2017;8:1679.","journal-title":"Front Immunol"},{"key":"13832_CR74","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","volume":"128","author":"K Brummel","year":"2023","unstructured":"Brummel K, Eerkens AL, De Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451\u20138.","journal-title":"Br J Cancer"},{"key":"13832_CR75","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/path.5406","volume":"250","author":"PI Gonzalez-Ericsson","year":"2020","unstructured":"Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020;250:667\u201384.","journal-title":"J Pathol"},{"key":"13832_CR76","doi-asserted-by":"publisher","first-page":"v608","DOI":"10.1093\/annonc\/mdx440.005","volume":"28","author":"S Loi","year":"2017","unstructured":"Loi S, Adams S, Schmid P, Cort\u00e9s J, Cescon DW, Winer EP, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Ann Oncol. 2017;28: v608.","journal-title":"Ann Oncol"},{"key":"13832_CR77","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","volume":"69","author":"AA Peters","year":"2009","unstructured":"Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen Receptor Inhibits Estrogen Receptor-\u03b1 Activity and Is Prognostic in Breast Cancer. Can Res. 2009;69:6131\u201340.","journal-title":"Can Res"},{"key":"13832_CR78","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3892\/ijo.2013.2151","volume":"44","author":"S Lyu","year":"2014","unstructured":"Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang J, et al. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER\u2212, PR\u2212, AR+ breast cancer. Int J Oncol. 2014;44:229\u201337.","journal-title":"Int J Oncol"},{"key":"13832_CR79","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.18632\/oncotarget.23196","volume":"9","author":"W Zhang","year":"2018","unstructured":"Zhang W, Liu X, Liu S, Qin Y, Tian X, Niu F, et al. Androgen receptor\/let-7a signaling regulates breast tumor-initiating cells. Oncotarget. 2018;9:3690\u2013703.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13832-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:14:56Z","timestamp":1741853696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13832-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13832"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13832-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, conducted in accordance with the principles of the World Medical Association Declaration of Helsinki and its later amendments, received approval from the Thematic Research Agency in Health and Life Sciences (ATRSSV, June 18, 2019). Informed consent was obtained from all participants involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}